Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OctoPlus, a Netherlands-based drug delivery and development company, has obtained full rights for the development of all applications of OP-145 through expansion of its license agreement for the compound with Leiden University Medical Center.
Subscribe to our email newsletter
The product candidate is currently in clinical development for the treatment of chronic middle ear infection, and is also showing potential in other indications such as sinusitis and disorders caused by the formation of bacterial biofilms.
OctoPlus first licensed OP-145 for clinical development from Leiden University Medical Center (LUMC) in 2004. With the new, amended agreement the company gains full control over the development of the product to include all applications and all forms of the product covered in its patent application. OctoPlus will pay LUMC an undisclosed upfront fee and royalties.
Promising results seen in the ongoing phase I/IIa study have further strengthened OctoPlus’ confidence in this product.
“We are delighted to have gained full control of OP-145 and its future potential. OctoPlus is committed to bringing this product to its full commercial value in a number of indications. We will continue our close cooperation with the Leiden University Medical Center during the future development of the product, whilst OP-145 is now a fully-owned product of OctoPlus,” said Dr Joost Holthuis, CEO of OctoPlus
OP-145 is a novel peptide product that has a unique mechanism of action. It neutralizes the bacterial toxins that often keep chronic middle ear infections active. OP-145 offers potential benefits to patients with chronic otitis media that do not respond to currently available antibiotics and thereby require surgical intervention.